AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy

NCT07009769 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 865

Last updated 2025-06-08

No results posted yet for this study

Summary

The investigators aim to develop an AI-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.

Conditions

Sponsors & Collaborators

  • Korea University Guro Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-16
Primary Completion
2024-12-31
Completion
2025-05-01

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07009769 on ClinicalTrials.gov